Innovent says trispecific antibody IBI3003 posts 84.6% ORR at Phase 1 RP2D in relapsed/refractory multiple myeloma

PUBT · 2d ago
Innovent says trispecific antibody IBI3003 posts 84.6% ORR at Phase 1 RP2D in relapsed/refractory multiple myeloma
  • Innovent disclosed updated Phase 1 results for IBI3003 in relapsed or refractory multiple myeloma at the 2026 IMS meeting.
  • Data supported a Phase 2 dose selection, with responses described as rapid, deep, and durable in heavily pretreated patients.
  • Management highlighted activity in high-risk disease, including cases with extramedullary involvement, a group with limited effective options.
  • Safety was characterized as manageable, with immune-related events largely low-grade and infections a key risk to monitor.
  • The readout underpins ongoing global Phase 1/2 trials, a China Phase 3 program, and a separate Phase 2 frontline combination study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290345PR_NEWS_USPR_____CN59025) on September 29, 2026, and is solely responsible for the information contained therein.